Infliximab desensitization in patients with inflammatory bowel diseases: a safe therapeutic alternative

References

• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476. doi: 10.1056/NEJMOA050516.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–333; quiz 591. doi: 10.1053/j.gastro.2005.11.030.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for crohn’s disease: the ACCENT I randomized trial. Lancet. 2002;359(9317):1541–1549. doi: 10.1016/S0140-6736(02)08512-4.
   PubMed Web of Science ®Google Scholar
• Pradeu T, Carosella ED. On the definition of a criterion of immunogenicity. Proc Natl Acad Sci U S A. 2006;103(47):17858–17861. doi: 10.1073/PNAS.0608683103.
   PubMed Web of Science ®Google Scholar
• Rup B, Pallardy M, Sikkema D, et al. Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the innovative medicines initiative ABIRISK consortium. Clin Exp Immunol. 2015;181(3):385–400. doi: 10.1111/CEI.12652.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Svenson M, Bendtzen K, et al. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn’s disease. J Crohns Colitis. 2012;6(1):108–111. doi: 10.1016/J.CROHNS.2011.08.001.
   PubMed Web of Science ®Google Scholar
• Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108(1):40–47; quiz 48. doi: 10.1038/AJG.2012.363.
   PubMed Web of Science ®Google Scholar
• Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59(1):49–54. doi: 10.1136/GUT.2009.183095.
   PubMed Web of Science ®Google Scholar
• Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4(10):1248–1254. doi: 10.1016/J.CGH.2006.06.025.
   PubMed Web of Science ®Google Scholar
• Lichtenstein L, Ron Y, Kivity S, et al. Infliximab-Related infusion reactions: systematic review. J Crohns Colitis. 2015;9(9):806–815. doi: 10.1093/ECCO-JCC/JJV096.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Svenson M, Bendtzen K, et al. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34(1):51–58. doi: 10.1111/J.1365-2036.2011.04682.X.
   PubMed Web of Science ®Google Scholar
• Ally MR, Betteridge JD, Veerappan GR. Delayed hypersensitivity reaction with infliximab: unusual to occur after initial dose. Inflamm Bowel Dis. 2012;18(8):E1592–3. doi: 10.1002/IBD.21909.
   PubMed Web of Science ®Google Scholar
• Hässler S, Bachelet D, Duhaze J, et al. Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: a prospective multicohort study of the ABIRISK consortium. PloS Med. 2020;17(10):e1003348. doi: 10.1371/JOURNAL.PMED.1003348.
   PubMed Web of Science ®Google Scholar
• Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-I patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341–353. doi: 10.1016/S2468-1253(19)30012-3.
   PubMed Web of Science ®Google Scholar
• Picoraro J, Winberry G, Siegel CA, et al. Premedication use prior to infliximab administration: a cross-sectional analysis. Inflamm Bowel Dis. 2017;23(1):174–180. doi: 10.1097/MIB.0000000000001002.
   PubMed Web of Science ®Google Scholar
• Tran-Minh ML, Gornet JM, Maillet M, et al. Safety of hydrocortisone premedication discontinuation in patients with inflammatory bowel disease on maintenance therapy with infliximab: a prospective clinical and pharmacological study. J Crohns Colitis. 2021;15(5):742–748. doi: 10.1093/ECCO-JCC/JJAA231.
   PubMed Web of Science ®Google Scholar
• Noon L. Prophylactic inoculation against hay fever. The Lancet. 1911;177(4580):1572–1573. doi: 10.1016/S0140-6736(00)78276-6.
   Google Scholar
• O'donovan WJ, Klorfajn I. Sensitivity to penicillin; anaphylaxis and desensitisation. Lancet. 1946;2(6422):444–446. doi: 10.1016/S0140-6736(46)90972-5.
   PubMedGoogle Scholar
• Makowska J, Lewandowska-Polak A. Desensitization to biological agents used in rheumatology. Reumatologia. 2020;58(1):25–33. doi: 10.5114/REUM.2020.93510.
   PubMedGoogle Scholar
• Mourad AA, Boktor MN, Yilmaz-Demirdag Y, et al. Adverse reactions to infliximab and the outcome of desensitization. Ann Allergy Asthma Immunol. 2015;115(2):143–146. doi: 10.1016/J.ANAI.2015.06.004.
   PubMed Web of Science ®Google Scholar
• Pauchard I, Nancey S, Hacard F, et al. Efficacy and safety of infliximab tolerance induction in patients with inflammatory bowel diseases who experienced acute infusion reactions. Dig Dis. 2018;36(6):417–426. doi: 10.1159/000491078.
   PubMed Web of Science ®Google Scholar
• Lelong J, Duburque C, Fournier C, et al. [Desensitisation to infliximab in patients with Crohn’s disease]. Rev Mal Respir. 2005;22(2 Pt 1):239–246. doi: 10.1016/S0761-8425(05)85477-4.
   PubMed Web of Science ®Google Scholar
• Brennan PJ, Bouza TR, Hsu FI, et al. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009;124(6):1259–1266. doi: 10.1016/J.JACI.2009.09.009.
   PubMed Web of Science ®Google Scholar
• Boschetti G, Nachury M, Laharie D, et al. Efficacy and safety of infliximab retreatment in Crohn’s disease: a multicentre, prospective, observational cohort (REGAIN) study from the GETAID. Am J Gastroenterol. 2022;117(9):1482–1490. doi: 10.14309/AJG.0000000000001842.
   PubMed Web of Science ®Google Scholar
• Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977;1(8009):466–469. doi: 10.1016/S0140-6736(77)91953-5.
   PubMed Web of Science ®Google Scholar
• Vega A, Peña MI, Torrado I. Use of rapid drug desensitization in delayed hypersensitivity reactions to chemotherapy and monoclonal antibodies. Front Allergy. 2021;2:786863. doi: 10.3389/FALGY.2021.786863.
   PubMedGoogle Scholar
• Le Cosquer G, Capirchio L, Rivière P, et al. Time trend in surgical indications and outcomes in ulcerative Colitis-A two decades in-depth retrospective analysis. Dig Liver Dis. 2023;55(10):1338–1344. doi: 10.1016/J.DLD.2023.03.003.
   PubMedGoogle Scholar
• Caimmi SME, Caimmi D, Riscassi S, et al. A new pediatric protocol for rapid desensitization to monoclonal antibodies. Int Arch Allergy Immunol. 2014;165(3):214–218. doi: 10.1159/000369299.
   PubMed Web of Science ®Google Scholar
• Behera SK, Selvarajan S, Mathews J, et al. A novel desensitization protocol for infliximab hypersensitivity in a 13-Year old patient with pustular psoriasis. Curr Drug Saf. 2019;14(2):158–162. doi: 10.2174/1574886314666190119115632.
   PubMed Web of Science ®Google Scholar
• Durham SR, Shamji MH. Allergen immunotherapy: past, present and future. Nat Rev Immunol. 2022 23:5 2022;23(5):317–328. doi: 10.1038/s41577-022-00786-1.
   PubMed Web of Science ®Google Scholar
• Roblin X, Marotte H, Leclerc M, et al. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease. J Crohns Colitis. 2015;9(7):525–531. doi: 10.1093/ecco-jcc/jjv061.
   PubMed Web of Science ®Google Scholar
• Atiqi S, Hooijberg F, Loeff FC, et al. Immunogenicity of TNF-Inhibitors. Front Immunol. 2020;11:312. doi: 10.3389/FIMMU.2020.00312.
   PubMed Web of Science ®Google Scholar
• Yerushalmy-Feler A, Olbjorn C, Kolho K-L, et al. Dual biologic or small molecule therapy in refractory pediatric inflammatory bowel disease (DOUBLE-PIBD): a multicenter study from the pediatric IBD Porto group of ESPGHAN. Inflamm Bowel Dis. 2023;30(2):159–166. doi: 10.1093/IBD/IZAD064.
   Web of Science ®Google Scholar
• Feagan BG, Sands BE, Sandborn WJ, et al. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA: a randomized, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023;8(4):307–320. doi: 10.1016/S2468-1253(22)00427-7.
   PubMed Web of Science ®Google Scholar
• Buisson A, Nachury M, Reymond M, et al. Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH study. Clin Gastroenterol Hepatol. 2022;21(9):2338–2346.e3. doi: 10.1016/J.CGH.2022.08.011.
   PubMed Web of Science ®Google Scholar
• D'Haens G, Reinisch W, Schreiber S, et al. Subcutaneous infliximab monotherapy versus combination therapy with immunosuppressants in inflammatory bowel disease: a post hoc analysis randomized clinical trial. Clin Drug Investig. 2023;43(4):277–288. doi: 10.1007/S40261-023-01252-Z.
   PubMed Web of Science ®Google Scholar